AG˹ٷ

STOCK TITAN

[Form 4] Delta Air Lines, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

The Form 144 filing indicates that an affiliate of KALA BIO, Inc. (KALA) plans to sell up to 13,227 shares of common stock through E*TRADE Financial on or about 24 June 2025. Using the filing’s stated market value of $53,040.27, the proposed sale represents roughly 0.2 % of the company’s 6,452,398 shares outstanding, suggesting limited dilution or market impact. The shares stem from a restricted-stock-unit (RSU) vesting that occurred the same day. The filer previously sold 10,866 shares for $40,638.84 earlier in June, signalling a pattern of modest insider dispositions. Form 144 is only a notice; the shares may or may not ultimately be sold, but it provides investors an early look at potential insider activity. No new operational, earnings, or strategic information about KALA BIO is furnished in this document.

La comunicazione del Modulo 144 indica che un affiliato di KALA BIO, Inc. (KALA) prevede di vendere fino a 13.227 azioni ordinarie tramite E*TRADE Financial intorno al 24 giugno 2025. Utilizzando il valore di mercato dichiarato nel modulo di 53.040,27 $, la vendita proposta rappresenta circa lo 0,2% delle 6.452.398 azioni in circolazione della società, suggerendo un impatto limitato su diluizione o mercato. Le azioni derivano da un vesting di unità azionarie vincolate (RSU) avvenuto lo stesso giorno. Il dichiarante aveva precedentemente venduto 10.866 azioni per 40.638,84 $ all'inizio di giugno, indicando una tendenza a disposizioni interne modeste. Il Modulo 144 è solo una notifica; le azioni potrebbero o meno essere effettivamente vendute, ma offre agli investitori una prima indicazione di potenziali movimenti interni. Nessuna nuova informazione operativa, sugli utili o strategica riguardante KALA BIO è fornita in questo documento.

La presentación del Formulario 144 indica que un afiliado de KALA BIO, Inc. (KALA) planea vender hasta 13,227 acciones ordinarias a través de E*TRADE Financial alrededor del 24 de junio de 2025. Usando el valor de mercado declarado en la presentación de $53,040.27, la venta propuesta representa aproximadamente el 0.2% de las 6,452,398 acciones en circulación de la compañía, lo que sugiere un impacto limitado en la dilución o en el mercado. Las acciones provienen de un vesting de unidades de acciones restringidas (RSU) ocurrido ese mismo día. El declarante previamente vendió 10,866 acciones por $40,638.84 a principios de junio, señalando un patrón de disposiciones internas modestas. El Formulario 144 es solo una notificación; las acciones pueden o no ser finalmente vendidas, pero ofrece a los inversores una mirada anticipada a la posible actividad interna. No se proporciona información nueva operativa, de ganancias o estratégica sobre KALA BIO en este documento.

Form 144 제출서에 따르� KALA BIO, Inc. (KALA)� 계열사가 2025� 6� 24�� E*TRADE Financial� 통해 최대 13,227주의 보통주를 판매� 계획임을 나타냅니�. 제출서에 명시� 시가총액 $53,040.27� 기준으로, 이번 판매� 회사� � 발행 주식 6,452,398주의 � 0.2%� 해당하여 희석이나 시장� 미치� 영향� 제한적임� 시사합니�. 해당 주식은 같은 � 발생� 제한 주식 단위(RSU) 베스�에서 나온 것입니다. 제출자는 6� 초에 이미 10,866주를 $40,638.84� 판매� � 있어, 내부� 매도 패턴� 다소 완만함을 보여줍니�. Form 144� 단지 통지서로, 주식� 실제� 매도될지 여부� 확정되지 않았지� 투자자에� 잠재� 내부� 활동� 미리 알려줍니�. � 문서에는 KALA BIO� 관� 새로� 운영, 수익 또는 전략 정보가 포함되어 있지 않습니다.

Le dépôt du formulaire 144 indique qu'une filiale de KALA BIO, Inc. (KALA) prévoit de vendre jusqu'à 13 227 actions ordinaires via E*TRADE Financial aux alentours du 24 juin 2025. En utilisant la valeur marchande déclarée dans le dépôt de 53 040,27 $, la vente proposée représente environ 0,2 % des 6 452 398 actions en circulation de l'entreprise, ce qui suggère un impact limité en termes de dilution ou de marché. Les actions proviennent d'une attribution d'unités d'actions restreintes (RSU) survenue le même jour. Le déclarant avait déjà vendu 10 866 actions pour 40 638,84 $ plus tôt en juin, indiquant un schéma de cessions internes modérées. Le formulaire 144 est seulement un avis ; les actions peuvent ou non être effectivement vendues, mais il offre aux investisseurs un aperçu anticipé d'une éventuelle activité interne. Aucun renseignement opérationnel, sur les résultats ou stratégique nouveau concernant KALA BIO n'est fourni dans ce document.

Die Einreichung des Formulars 144 zeigt an, dass ein verbundenes Unternehmen von KALA BIO, Inc. (KALA) plant, bis zu 13.227 Stammaktien über E*TRADE Financial etwa am 24. Juni 2025 zu verkaufen. Basierend auf dem im Formular angegebenen Marktwert von 53.040,27 $ entspricht der geplante Verkauf etwa 0,2 % der 6.452.398 ausstehenden Aktien des Unternehmens, was auf eine begrenzte Verwässerung oder Markteinwirkung hindeutet. Die Aktien stammen von einer Restricted-Stock-Unit (RSU) Vesting, die am selben Tag stattfand. Der Einreicher hatte bereits Anfang Juni 10.866 Aktien für 40.638,84 $ verkauft, was auf ein Muster moderater Insider-Verkäufe hinweist. Das Formular 144 ist lediglich eine Mitteilung; die Aktien müssen nicht zwangsläufig verkauft werden, bietet Investoren jedoch einen frühen Einblick in potenzielle Insider-Aktivitäten. In diesem Dokument werden keine neuen operativen, Gewinn- oder strategischen Informationen zu KALA BIO bereitgestellt.

Positive
  • None.
Negative
  • Insider selling: Notice covers 13,227 shares plus 10,866 sold earlier, which can be perceived as bearish sentiment.
  • Potential supply overhang: Even small sales can pressure thinly traded stocks, though impact depends on daily volume.

Insights

TL;DR: Minor insider sale (0.2 % float); sentiment mildly negative but financial impact negligible.

The proposed sale of 13.2 k shares—valued at about $53 k—has virtually no dilutive effect on KALA BIO’s capital structure. However, consecutive Form 144s combined with last month’s 10.9 k-share sale can be interpreted as cautious insider sentiment. Because the filing lacks any business updates or revised forecasts, it should be viewed as neutral-to-slightly-negative: marginal supply overhang and optics of insider selling but no change to fundamentals.

La comunicazione del Modulo 144 indica che un affiliato di KALA BIO, Inc. (KALA) prevede di vendere fino a 13.227 azioni ordinarie tramite E*TRADE Financial intorno al 24 giugno 2025. Utilizzando il valore di mercato dichiarato nel modulo di 53.040,27 $, la vendita proposta rappresenta circa lo 0,2% delle 6.452.398 azioni in circolazione della società, suggerendo un impatto limitato su diluizione o mercato. Le azioni derivano da un vesting di unità azionarie vincolate (RSU) avvenuto lo stesso giorno. Il dichiarante aveva precedentemente venduto 10.866 azioni per 40.638,84 $ all'inizio di giugno, indicando una tendenza a disposizioni interne modeste. Il Modulo 144 è solo una notifica; le azioni potrebbero o meno essere effettivamente vendute, ma offre agli investitori una prima indicazione di potenziali movimenti interni. Nessuna nuova informazione operativa, sugli utili o strategica riguardante KALA BIO è fornita in questo documento.

La presentación del Formulario 144 indica que un afiliado de KALA BIO, Inc. (KALA) planea vender hasta 13,227 acciones ordinarias a través de E*TRADE Financial alrededor del 24 de junio de 2025. Usando el valor de mercado declarado en la presentación de $53,040.27, la venta propuesta representa aproximadamente el 0.2% de las 6,452,398 acciones en circulación de la compañía, lo que sugiere un impacto limitado en la dilución o en el mercado. Las acciones provienen de un vesting de unidades de acciones restringidas (RSU) ocurrido ese mismo día. El declarante previamente vendió 10,866 acciones por $40,638.84 a principios de junio, señalando un patrón de disposiciones internas modestas. El Formulario 144 es solo una notificación; las acciones pueden o no ser finalmente vendidas, pero ofrece a los inversores una mirada anticipada a la posible actividad interna. No se proporciona información nueva operativa, de ganancias o estratégica sobre KALA BIO en este documento.

Form 144 제출서에 따르� KALA BIO, Inc. (KALA)� 계열사가 2025� 6� 24�� E*TRADE Financial� 통해 최대 13,227주의 보통주를 판매� 계획임을 나타냅니�. 제출서에 명시� 시가총액 $53,040.27� 기준으로, 이번 판매� 회사� � 발행 주식 6,452,398주의 � 0.2%� 해당하여 희석이나 시장� 미치� 영향� 제한적임� 시사합니�. 해당 주식은 같은 � 발생� 제한 주식 단위(RSU) 베스�에서 나온 것입니다. 제출자는 6� 초에 이미 10,866주를 $40,638.84� 판매� � 있어, 내부� 매도 패턴� 다소 완만함을 보여줍니�. Form 144� 단지 통지서로, 주식� 실제� 매도될지 여부� 확정되지 않았지� 투자자에� 잠재� 내부� 활동� 미리 알려줍니�. � 문서에는 KALA BIO� 관� 새로� 운영, 수익 또는 전략 정보가 포함되어 있지 않습니다.

Le dépôt du formulaire 144 indique qu'une filiale de KALA BIO, Inc. (KALA) prévoit de vendre jusqu'à 13 227 actions ordinaires via E*TRADE Financial aux alentours du 24 juin 2025. En utilisant la valeur marchande déclarée dans le dépôt de 53 040,27 $, la vente proposée représente environ 0,2 % des 6 452 398 actions en circulation de l'entreprise, ce qui suggère un impact limité en termes de dilution ou de marché. Les actions proviennent d'une attribution d'unités d'actions restreintes (RSU) survenue le même jour. Le déclarant avait déjà vendu 10 866 actions pour 40 638,84 $ plus tôt en juin, indiquant un schéma de cessions internes modérées. Le formulaire 144 est seulement un avis ; les actions peuvent ou non être effectivement vendues, mais il offre aux investisseurs un aperçu anticipé d'une éventuelle activité interne. Aucun renseignement opérationnel, sur les résultats ou stratégique nouveau concernant KALA BIO n'est fourni dans ce document.

Die Einreichung des Formulars 144 zeigt an, dass ein verbundenes Unternehmen von KALA BIO, Inc. (KALA) plant, bis zu 13.227 Stammaktien über E*TRADE Financial etwa am 24. Juni 2025 zu verkaufen. Basierend auf dem im Formular angegebenen Marktwert von 53.040,27 $ entspricht der geplante Verkauf etwa 0,2 % der 6.452.398 ausstehenden Aktien des Unternehmens, was auf eine begrenzte Verwässerung oder Markteinwirkung hindeutet. Die Aktien stammen von einer Restricted-Stock-Unit (RSU) Vesting, die am selben Tag stattfand. Der Einreicher hatte bereits Anfang Juni 10.866 Aktien für 40.638,84 $ verkauft, was auf ein Muster moderater Insider-Verkäufe hinweist. Das Formular 144 ist lediglich eine Mitteilung; die Aktien müssen nicht zwangsläufig verkauft werden, bietet Investoren jedoch einen frühen Einblick in potenzielle Insider-Aktivitäten. In diesem Dokument werden keine neuen operativen, Gewinn- oder strategischen Informationen zu KALA BIO bereitgestellt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PRABHU VASANT M

(Last) (First) (Middle)
C/O DELTA AIR LINES, INC., DEPT. 981
1030 DELTA BOULEVARD

(Street)
ATLANTA GA 30354

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DELTA AIR LINES, INC. [ DAL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A 4,240(1) A (1) 12,720 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Non-employee members of Delta's Board of Directors receive an annual restricted stock award valued at $200,000. The shares reported in this Form 4 represent the annual restricted stock award grant to the Reporting Person, as approved by the Board of Directors on June 19, 2025. Because June 19, 2025 was a federal holiday, the grant date for the restricted stock award is deemed to be the next trading day (Friday, June 20, 2025) in accordance with Delta's Equity Award Grant Policy. The shares were acquired in a transaction exempt under Rule 16b-3(d)(1).
/s/ Alan T. Rosselot as attorney-in-fact for Vasant M. Prabhu 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many KALA shares are included in the latest Form 144?

The filing covers 13,227 shares of KALA common stock.

What is the estimated value of the proposed KALA insider sale?

The aggregate market value reported is approximately $53,040.27.

What percentage of KALA’s shares outstanding does the proposed sale represent?

About 0.2 % of the reported 6,452,398 shares outstanding.

When is the approximate sale date stated in the Form 144 for KALA?

The filer plans to sell on or around 24 June 2025.

How many KALA shares did the same filer sell in the past three months?

The filer disposed of 10,866 shares for gross proceeds of $40,638.84 earlier in June 2025.
Delta Air Lines Inc Del

NYSE:DAL

DAL Rankings

DAL Latest News

DAL Latest SEC Filings

DAL Stock Data

32.73B
650.31M
0.36%
82.83%
4.1%
Airlines
Air Transportation, Scheduled
United States
ATLANTA